Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
	Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America
	FDA Extends PDUFA Action Date for STEDESA™ New Drug Application
	Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia